QIMING U S VENTURES MANAGEMENT LLC
Q4 2022 Form 13-F
BELLEVUE, WASHINGTON
CIK 0001909617
· CRD 287471
· Exempt reporting adviser
$75.6M Reported Value Total
Exempt Reporting Adviser
qimingvcusa.com
Source: Form ADV filed 2026-03-30
Reported value
$75.6M
Quarter over quarter
+9.8%
Holdings
7
Top-10 concentration
100.0%
Key People
Named on the latest Form 13-F filing — not necessarily an owner
Ryan Baker
Chief Financial Officer
Filing Navigation
13F Metrics
Loading 13F Metrics
Q4 2022 13F record
Q4 2022 13F filing summary
| Period of report | December 31, 2022 |
|---|---|
| Filed | January 24, 2023 |
| Form | 13F-HR |
| Reported value | $75.6M |
| Positions | 7 |
| Change in reported value | +9.8% |
| New positions | 0 |
| Exited positions | 0 |
| Position turnover | 0.0% |
| Top-10 concentration | 100.0% |
13F filings by quarter
| Quarter | Positions | Value |
|---|---|---|
|
Q3 2025 13F
Filed Nov 10, 2025
|
4 | $55.6M |
|
Q2 2025 13F
Filed Aug 14, 2025
|
6 | $23.6M |
|
Q1 2025 13F
Filed May 15, 2025
|
6 | $23.1M |
|
Q4 2024 13F
Filed Jan 28, 2025
|
6 | $51.1M |
|
Q3 2024 13F
Filed Nov 7, 2024
|
6 | $51.4M |
|
Q2 2024 13F
Filed Aug 13, 2024
|
6 | $52.6M |
|
Q1 2024 13F
Filed May 14, 2024
|
6 | $89.7M |
|
Q4 2023 13F
Filed Feb 14, 2024
|
8 | $109.2M |
|
Q3 2023 13F
Filed Nov 9, 2023
|
7 | $75.3M |
|
Q2 2023 13F
Filed Jul 24, 2023
|
7 | $95.2M |
|
Q1 2023 13F
Filed Apr 25, 2023
|
7 | $82.6M |
|
Q4 2022 13F
Filed Jan 24, 2023
|
7 | $75.6M |
|
Q3 2022 13F
Filed Nov 8, 2022
|
7 | $68.8M |
|
Q2 2022 13F
Filed Jul 22, 2022
|
7 | $72.0M |
|
Q1 2022 13F
Filed May 16, 2022
|
6 | $106.4M |
|
Q4 2021 13F
Filed Feb 14, 2022
|
6 | $217.3M |
Top 7 holdings · Q4 2022
| # | Holding | Reported value | % of portfolio |
|---|---|---|---|
| 1 | ICVX ICOSAVAX INC | $27.9M | 36.87% |
| 2 | VTYX VENTYX BIOSCIENCES INC | $24.5M | 32.37% |
| 3 | HLVX HILLEVAX INC | $9.4M | 12.37% |
| 4 | KZR KEZAR LIFE SCIENCES INC | $5.8M | 7.72% |
| 5 | TALS TALARIS THERAPEUTICS INC | $3.0M | 3.96% |
| 6 | JSPR JASPER THERAPEUTICS INC | $2.8M | 3.74% |
| 7 | ELEV ELEVATION ONCOLOGY INC | $2.3M | 2.98% |
Values as reported on the Q4 2022 Form 13F. Every position is in the holdings table below.